Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 3/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.50 |
| ▸ | PIK3R1 | P27986 | 3/20 | 0.49 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.46 |
| ▸ | MTOR | P42345 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17673774 | 1.00 | MAPT (0.56) | MAPTCYP1A2CYP2D6KMT2AMEN1 | |
| SCHEMBL855348 | 0.89 | MAPT (0.68) | MAPTCYP1A2CYP2D6KMT2AMEN1 | |
| SCHEMBL5480430 | 0.87 | KMT2A (0.68) | MAPTCYP1A2CYP2D6KMT2AMEN1 | |
| SCHEMBL244109 | 0.87 | MAPT (0.57) | MAPTCYP1A2CYP2D6KMT2AMEN1 | |
| SCHEMBL17859805 | 0.86 | MAPT (0.47) | MAPTCYP1A2CYP2D6KMT2AMEN1 | |
| SCHEMBL19479135 | 0.84 | CYP1A2 (0.62) | MAPTCYP1A2CYP2D6KMT2AMEN1 | |
| SCHEMBL17859810 | 0.83 | PIK3CA (0.47) | MAPTCYP1A2CYP2D6KMT2AMEN1 | |
| SCHEMBL12986387 | 0.83 | KMT2A (0.46) | MAPTCYP1A2CYP2D6KMT2AMEN1 | |
| SCHEMBL3991404 | 0.83 | MAPT (0.51) | MAPTCYP1A2CYP2D6KMT2AMEN1 | |
| SCHEMBL17859811 | 0.83 | MAPT (0.45) | MAPTCYP1A2CYP2D6KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 289 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12497407-B2 | Treatment of skin disorders | TORQUR AG (CH) | 2025-12-16 | — | — | US | disclosed |
| US-20250197375-A1 | PYRIMIDINES AND METHODS OF THEIR USE | Kineta, Inc. | 2025-06-19 | — | — | US | disclosed |
| US-12312336-B2 | Inhibitors of RAF kinases | Pierre Fabre Médicament (FR) | 2025-05-27 | — | — | US | disclosed |
| US-20240382496-A1 | TREATMENT OF SKIN LESIONS | TORQUR AG (CH) | 2024-11-21 | — | — | US | disclosed |
| CN-118922188-A | Pyrimidine and methods of use thereof | 奇尼塔公司 | 2024-11-08 | — | — | CN | disclosed |
| US-20240343718-A1 | TREATMENT OF NEUROLOGICAL DISORDERS | TORQUR AG (CH) | 2024-10-17 | — | — | US | disclosed |
| EP-4444309-A1 | PYRIMIDINES AND METHODS OF THEIR USE | Kineta, Inc. (US) | 2024-10-16 | — | — | EP | disclosed |
| CN-114845711-B | Inhibitors of RAF kinase | 皮埃尔法布雷医药公司 | 2024-10-01 | — | — | CN | disclosed |
| US-11935803-B2 | Resin composition, laminate, semiconductor wafer with resin composition layer, substrate for mounting semiconductor with resin composition layer and semiconductor device | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2024-03-19 | — | — | US | disclosed |
| US-11918586-B2 | Treatment of skin lesions | TORQUR AG (CH) | 2024-03-05 | — | — | US | disclosed |
| US-6995153-B2 | Fused bicyclic pyrimidine derivatives | KYORIN PHARMACEUTICAL. CO., LTD. (JP) | 2006-02-07 | — | — | US | disclosed |
| US-20050085469-A1 | Fused bicyclic pyrimidine derivatives | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2005-04-21 | — | — | US | disclosed |
| WO-2005007648-A2 | BIARYL PIPERAZINYL-PYRIDINE ANALOGUES | NEUROGEN CORPORATION (US) | 2005-01-27 | — | — | WO | disclosed |
| WO-2005007646-A1 | SUBSTITUTED HETEROCYCLIC DIARYLAMINE ANALOGUES | NEUROGEN CORPORATION (US) | 2005-01-27 | — | — | WO | disclosed |
| EP-1473295-A1 | FUSED BICYCLIC PYRIMIDINE DERIVATIVES | Kyorin Pharmaceutical Co., Ltd. (JP) | 2004-11-03 | — | — | EP | disclosed |
| EP-0713875-B1 | Sulfonamides | HOFFMANN LA ROCHE (CH) | 2001-03-21 | — | — | EP | disclosed |
| US-5837708-A | CARDIOVASCULAR DISORDERS OF HYPERTENSION, ISCHEMIA, ANGINA PECTORIS AND VASOSPASMS | HOFFMANN-LA ROCHE INC. (US) | 1998-11-17 | — | — | US | disclosed |
| WO-1996016963-A1 | SULFONAMIDES AND THEIR USE AS MEDICAMENTS | F. HOFFMANN-LA ROCHE AG (CH) | 1996-06-06 | — | — | WO | disclosed |
| EP-0713875-A1 | Sulfonamides | F. Hoffmann-La Roche AG (CH) | 1996-05-29 | — | — | EP | disclosed |
| US-3984411-A | HYPOCHOLESTEROLEMICS, HYPOGLYCEMICS OR ANTIDIABETICS | SOCIETE GENERALE DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES "SOGERAS" (FR) | 1976-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085469-A1 | Fused bicyclic pyrimidine derivatives | BDKRB1, BDKRB2, TACR1 | MAPT 4319/4885CYP1A2 3652/4885CYP2D6 3129/4885 |
| US-20240382496-A1 | TREATMENT OF SKIN LESIONS | C1R, C3AR1, CXCR3 | MAPT 2395/4885CYP1A2 303/4885CYP2D6 348/4885 |
| US-20240343718-A1 | TREATMENT OF NEUROLOGICAL DISORDERS | CHRM2, CHRM1, C1R | MAPT 261/4885CYP1A2 136/4885CYP2D6 146/4885 |
| US-12497407-B2 | Treatment of skin disorders | RXFP3, CCR3, CBR3 | MAPT 2061/4885CYP1A2 405/4885CYP2D6 638/4885 |
| US-20250197375-A1 | PYRIMIDINES AND METHODS OF THEIR USE | TDP1, TYMP, TARDBP | MAPT 7/4885CYP1A2 3915/4885CYP2D6 3717/4885 |
| US-11918586-B2 | Treatment of skin lesions | C1R, C3AR1, CXCR3 | MAPT 2395/4885CYP1A2 303/4885CYP2D6 348/4885 |
| US-12312336-B2 | Inhibitors of RAF kinases | BRAF, RAF1, ARAF | MAPT 2859/4885CYP1A2 4302/4885CYP2D6 4339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.